Developer docs
API playgroundTry for free, no card

Search company profiles

BioReperia

Full company profile

uuid0004p47

Namestring
BioReperia
Legal namestring
BioReperia AB
Websiteurl
bioreperia.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

BioReperia AB is a Swedish preclinical oncology company founded in September 2015 by Anna Fahlgren and Lasse Jensen, based on zebrafish tumor xenograft technology developed at Linköping University. The company operates its ZTX (Zebrafish Tumor Xenograft) platform, which uses humanized zebrafish embryos as in-vivo hosts for patient-derived and cell-line-derived tumor xenografts, enabling evaluation of drug efficacy, metastasis inhibition, and immune oncology responses within five days. BioReperia commercializes the platform through two product lines: ZTX ONCOLEADS, a contract research service offering for biopharmaceutical companies, biotech firms, and academic institutions conducting preclinical oncology drug discovery (tumor efficacy, metastasis, immune oncology, toxicology, screening, disease modeling); and ZTX PREDICT, a CE-certified precision medicine diagnostic service for clinical healthcare providers that tests patient tumor biopsies to identify the most effective anti-cancer treatment within five days for clinical decision support. The clinical laboratory is ISO-13485 and ISO-15189 compliant.

The company generates revenue through quote-based professional services contracts — typically multi-year project engagements priced by scope, number of models, cell lines, and experimental endpoints — with named customers including CIS Biopharma AG, Noxopharm Ltd, Glycyx MOR Inc, ImmunoFyx, Cantargia AB, Charles River Laboratories, and Linköping University. Distribution is primarily direct enterprise sales, supplemented by a strategic channel partnership with Charles River Laboratories (which embeds the ZTX platform in CRL's global PDX Tumor Compendium offering) and a wholly-owned Swiss subsidiary established in December 2019 via Hemex AG incubator to serve the DACH region. BioReperia has raised a Series A funding round (~$830K, 2019) and participates in the EU H2020-MSCA-RISE consortium. The company is headquartered in Linköping, Sweden, with approximately 7-8 employees, and underwent a leadership transition in March 2026 appointing Emmelie Persson as CEO and Anna Erkstam as Chief Business Officer.

Short descriptiontext

BioReperia AB is a Swedish preclinical oncology CRO that uses its proprietary Zebrafish Tumor Xenograft (ZTX) platform to deliver in-vivo drug efficacy, metastasis, and immune oncology readouts to biopharma clients within five days, and offers a CE-certified ZTX PREDICT precision medicine diagnostic service to clinical oncology providers for individualized cancer treatment selection.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLinköping, Sweden
HQ citystring
Linköping
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
zebrafish xenograft models, preclinical oncology services, drug discovery CRO, precision medicine diagnostics, patient-derived xenograft research
Industry4 codes
PRIMARYHLAGAEAI
Sample Logistics, Biorepository & IVD Kit Management (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Preclinical Oncology Drug Discovery Services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research Services (CRO)
TypeProfessional Services
Description

BioReperia provides fee-for-service research contracts to pharmaceutical companies, biotech firms, and academic institutions. Services include tumor efficacy testing, metastasis evaluation, immune oncology studies, toxicology assessments, and disease model studies. Pricing is quote-based with project-specific scope.

bioreperia.com
2Clinical Diagnostic Services (ZTX PREDICT)
TypeProfessional Services
Description

CE-certified diagnostic service for clinical providers that tests patient tumor biopsies to identify most effective cancer treatments within 5 days. Laboratory is ISO-13485 and ISO-15189 compliant. Provides treatment planning tool for clinical oncology.

bioreperia.com
3Patient Stratification for Clinical Trials
TypeProfessional Services
Description

Pharmaceutical companies use ZTX platform as inclusion criteria for clinical trials, testing patient tumor cells for sensitivity to specific treatments to identify responders and include only responsive patients.

bioreperia.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom contract research pricing based on project scope
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing; no public price list available. Projects vary based on number of models, compounds, cell lines, and experimental endpoints.

bioreperia.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1ZTX PREDICT
Description

A CE-certified Zebrafish Tumor Xenograft platform that identifies the most efficient anti-cancer drug for individual patients within 5 days, providing clinical decision support for pharmaceutical or surgical treatment.

bioreperia.com
+2 more records
Core offering1 text field

BioReperia provides contract research services using its proprietary Zebrafish Tumor Xenograft (ZTX) platform for preclinical oncology drug discovery and a CE-certified precision medicine diagnostic service. The biopharma offering (ZTX ONCOLEADS) evaluates tumor efficacy, metastasis, immune oncology, screening, toxicology, and disease models, delivering lead candidate selection in 5 days. The clinical offering (ZTX PREDICT) tests patient tumor biopsies to identify the most effective cancer treatment for individual patients within 5 days, serving pharmaceutical companies, biotech firms, academic institutions, and clinical healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Treatment prediction accuracy of 80% compared to clinical outcomes
+6 more records
Product overview1 text field

BioReperia offers a unified ZTX (Zebrafish Tumor Xenograft) platform with two distinct product lines: ZTX ONCOLEADS for drug discovery (biopharma/academia) and ZTX PREDICT for precision medicine (clinical providers/patients). The platform leverages zebrafish embryos as an in-vivo model system to evaluate drug efficacy, tumor regression, and metastasis inhibition within 5 days. Both products share the core ZTX technology but serve different market segments - ONCOLEADS accelerates preclinical drug development while PREDICT enables individualized cancer treatment selection. The platform is CE-certified for clinical use and complies with ISO-13485 and ISO-15189 standards.

Product and service3 records
1ZTX ONCOLEADS
CategoryPreclinical Drug Discovery Services
Description

Humanized in-vivo oncology drug discovery platform that mimics the complex tumor environment using the proprietary ZTX zebrafish xenograft technology, enabling biopharmaceutical and academic clients to select the best lead candidates for further pharmaceutical development within 5 days. Used for preclinical drug efficacy, metastasis, immune oncology, screening, toxicology, and disease model studies.

2ZTX PREDICT
CategoryClinical Precision Medicine Diagnostics
Description

CE-certified precision medicine diagnostic service that tests patient tumor biopsies in BioReperia's ISO-13485/ISO-15189 compliant laboratory to identify the most efficient anti-cancer drug for individual patients within 5 days, providing clinical decision support for pharmaceutical or surgical treatment selection and metastasis risk assessment. Services clinical healthcare providers and supports patient stratification for clinical trials.

3ZTX Platform (Parent Technology)
CategoryCore Proprietary Technology Platform
Description

The proprietary Zebrafish Tumor Xenograft (ZTX) platform providing in-vivo data on tumor regression and metastasis inhibition of compounds within 5 days, enabling rapid oncology drug screening and clinical decision support. The platform underpins both ZTX ONCOLEADS and ZTX PREDICT offerings, leveraging zebrafish embryos' transparency, undeveloped immune systems, and rapid vascularization.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-12-18
Description

Strategic partnership where Charles River Laboratories provides access to their Tumor Compendium of over 1000 fully characterized PDX models. The ZTX platform supports all PDX models from Charles River, and collaborative studies have been presented at AACR conferences. The partnership enables pharmaceutical companies to screen PDX models using the zebrafish platform before mouse studies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Co-hosted webinar on 'Advancing Human Disease Research with Zebrafish Models: From Tank to Bedside' with Joseph Bruckner, PhD from InVivo Biosystems. Partnership for knowledge sharing and cross-promotion in zebrafish model research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner service provider offering advanced drug discovery services including biomarker analysis, disease modeling, and preclinical screening. Collaboration for joint service delivery and market expansion.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration for pre-clinical evaluation of CAN04 antibody for lung and pancreatic cancer. AACR 2020 poster presentation showed synergistic effects of CAN04 with cisplatin, including anti-metastatic activity in cisplatin-resistant models.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner for co-hosted webinar on 'Advancing Prostate Cancer Targeted Therapy: Breakthroughs Using Zebrafish Tumor Xenograft Models' with Sujit Nair, PhD from Icahn School of Medicine at Mount Sinai.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration for evaluation of checkpoint inhibitors and autologous T cell activation on primary tumor tissue using zebrafish tumor xenograft models.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration contributing to AML study published in Leukemia journal, strengthening validation of DCPS as therapeutic target for acute myeloid leukemia.

8Region Östergötland
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Regional healthcare provider collaboration for ovarian cancer patient treatment planning using zebrafish tumor-derived xenograft models.

bioreperia.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CRO/CDMO with comprehensive preclinical oncology and drug discovery services. Competes for the same biopharma preclinical budgets though with a much broader service portfolio.

TypeBroad incumbent
Description

Global CRO with extensive preclinical oncology and PDX model offerings, and BioReperia's principal strategic channel partner for Tumor Compendium access. Comparable as an oncology preclinical services incumbent, though much broader in scope.

TypeEmerging player
Description

Specialized zebrafish CRO offering in-vivo disease modeling and toxicology services. Direct competitor in zebrafish-based preclinical research and listed BioReperia partner.

TypeBroad incumbent
Description

Global preclinical and translational CRO with a large PDX and oncology model portfolio. Comparable as a competitor for preclinical oncology drug discovery budgets at biopharma customers.

TypeDirect peer
Description

Specialized oncology CRO focused on patient-derived xenograft models, tumor profiling, and preclinical drug development. Closely comparable service offering for biopharma preclinical programs.

TypeDirect peer
Description

Zebrafish-focused CRO providing preclinical drug discovery, safety pharmacology, and toxicity services. Direct competitor in zebrafish-based CRO services for pharma and biotech.

7Phylonix Services
TypeDirect peer
Description

Early commercial zebrafish CRO offering in-vivo drug efficacy and toxicity assessments. Direct competitor in the same zebrafish preclinical services niche.

TypeBroad incumbent
Description

Preclinical CRO with model development, toxicology, and translational research services, including oncology models. Comparable as a broad preclinical services competitor.

TypeEmerging player
Description

Partner and emerging CRO offering biomarker analysis, disease modeling, and preclinical screening services, including zebrafish expertise. Comparable as a smaller emerging preclinical CRO with adjacent capabilities.

TypeEmerging player
Description

Specialized preclinical CRO with focus on patient-derived and humanized models for oncology and immuno-oncology drug development. Comparable emerging player in preclinical oncology CRO services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioReperia

Preclinical Oncology Drug Discovery Servicesbioreperia.com

BioReperia AB is a Swedish preclinical oncology CRO that uses its proprietary Zebrafish Tumor Xenograft (ZTX) platform to deliver in-vivo drug efficacy, metastasis, and immune oncology readouts to biopharma clients within five days, and offers a CE-certified ZTX PREDICT precision medicine diagnostic service to clinical oncology providers for individualized cancer treatment selection.

What BioReperia does

BioReperia AB is a Swedish preclinical oncology company founded in September 2015 by Anna Fahlgren and Lasse Jensen, based on zebrafish tumor xenograft technology developed at Linköping University. The company operates its ZTX (Zebrafish Tumor Xenograft) platform, which uses humanized zebrafish embryos as in-vivo hosts for patient-derived and cell-line-derived tumor xenografts, enabling evaluation of drug efficacy, metastasis inhibition, and immune oncology responses within five days. BioReperia commercializes the platform through two product lines: ZTX ONCOLEADS, a contract research service offering for biopharmaceutical companies, biotech firms, and academic institutions conducting preclinical oncology drug discovery (tumor efficacy, metastasis, immune oncology, toxicology, screening, disease modeling); and ZTX PREDICT, a CE-certified precision medicine diagnostic service for clinical healthcare providers that tests patient tumor biopsies to identify the most effective anti-cancer treatment within five days for clinical decision support. The clinical laboratory is ISO-13485 and ISO-15189 compliant.

The company generates revenue through quote-based professional services contracts — typically multi-year project engagements priced by scope, number of models, cell lines, and experimental endpoints — with named customers including CIS Biopharma AG, Noxopharm Ltd, Glycyx MOR Inc, ImmunoFyx, Cantargia AB, Charles River Laboratories, and Linköping University. Distribution is primarily direct enterprise sales, supplemented by a strategic channel partnership with Charles River Laboratories (which embeds the ZTX platform in CRL's global PDX Tumor Compendium offering) and a wholly-owned Swiss subsidiary established in December 2019 via Hemex AG incubator to serve the DACH region. BioReperia has raised a Series A funding round (~$830K, 2019) and participates in the EU H2020-MSCA-RISE consortium. The company is headquartered in Linköping, Sweden, with approximately 7-8 employees, and underwent a leadership transition in March 2026 appointing Emmelie Persson as CEO and Anna Erkstam as Chief Business Officer.

BioReperia firmographics

Firmographics
Name
BioReperia
Legal name
BioReperia AB
Website
https://bioreperia.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
BioReperia AB is a Swedish preclinical oncology CRO that uses its proprietary Zebrafish Tumor Xenograft (ZTX) platform to deliver in-vivo drug efficacy, metastasis, and immune oncology readouts to biopharma clients within five days, and offers a CE-certified ZTX PREDICT precision medicine diagnostic service to clinical oncology providers for individualized cancer treatment selection.
Ownership category
akta.pro rank

BioReperia industry classification

Industry
Product category
Preclinical Oncology Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAEAI
Sample Logistics, Biorepository & IVD Kit Management (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Zebrafish xenograft models
  • Preclinical oncology services
  • Drug discovery CRO
  • Precision medicine diagnostics
  • Patient-derived xenograft research

Where BioReperia is headquartered

Location

Headquarters

HQ city
Linköping
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

BioReperia business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Services (CRO): BioReperia provides fee-for-service research contracts to pharmaceutical companies, biotech firms, and academic institutions. Services include tumor efficacy testing, metastasis evaluation, immune oncology studies, toxicology assessments, and disease model studies. Pricing is quote-based with project-specific scope.
  2. Clinical Diagnostic Services (ZTX PREDICT): CE-certified diagnostic service for clinical providers that tests patient tumor biopsies to identify most effective cancer treatments within 5 days. Laboratory is ISO-13485 and ISO-15189 compliant. Provides treatment planning tool for clinical oncology.
  3. Patient Stratification for Clinical Trials: Pharmaceutical companies use ZTX platform as inclusion criteria for clinical trials, testing patient tumor cells for sensitivity to specific treatments to identify responders and include only responsive patients.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom contract research pricing based on project scope

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

BioReperia product offering

Product offering

Core offering

BioReperia provides contract research services using its proprietary Zebrafish Tumor Xenograft (ZTX) platform for preclinical oncology drug discovery and a CE-certified precision medicine diagnostic service. The biopharma offering (ZTX ONCOLEADS) evaluates tumor efficacy, metastasis, immune oncology, screening, toxicology, and disease models, delivering lead candidate selection in 5 days. The clinical offering (ZTX PREDICT) tests patient tumor biopsies to identify the most effective cancer treatment for individual patients within 5 days, serving pharmaceutical companies, biotech firms, academic institutions, and clinical healthcare providers.

Product overview

BioReperia offers a unified ZTX (Zebrafish Tumor Xenograft) platform with two distinct product lines: ZTX ONCOLEADS for drug discovery (biopharma/academia) and ZTX PREDICT for precision medicine (clinical providers/patients). The platform leverages zebrafish embryos as an in-vivo model system to evaluate drug efficacy, tumor regression, and metastasis inhibition within 5 days. Both products share the core ZTX technology but serve different market segments - ONCOLEADS accelerates preclinical drug development while PREDICT enables individualized cancer treatment selection. The platform is CE-certified for clinical use and complies with ISO-13485 and ISO-15189 standards.

Differentiator

Problem solved

Functional benefit

Brands

  • ZTX PREDICT: A CE-certified Zebrafish Tumor Xenograft platform that identifies the most efficient anti-cancer drug for individual patients within 5 days, providing clinical decision support for pharmaceutical or surgical treatment.
  • ZTX ONCOLEADS
  • ZTX Platform

Products and services

  • ZTX ONCOLEADS Humanized in-vivo oncology drug discovery platform that mimics the complex tumor environment using the proprietary ZTX zebrafish xenograft technology, enabling biopharmaceutical and academic clients to select the best lead candidates for further pharmaceutical development within 5 days. Used for preclinical drug efficacy, metastasis, immune oncology, screening, toxicology, and disease model studies.
  • ZTX PREDICT CE-certified precision medicine diagnostic service that tests patient tumor biopsies in BioReperia's ISO-13485/ISO-15189 compliant laboratory to identify the most efficient anti-cancer drug for individual patients within 5 days, providing clinical decision support for pharmaceutical or surgical treatment selection and metastasis risk assessment. Services clinical healthcare providers and supports patient stratification for clinical trials.
  • ZTX Platform (Parent Technology) The proprietary Zebrafish Tumor Xenograft (ZTX) platform providing in-vivo data on tumor regression and metastasis inhibition of compounds within 5 days, enabling rapid oncology drug screening and clinical decision support. The platform underpins both ZTX ONCOLEADS and ZTX PREDICT offerings, leveraging zebrafish embryos' transparency, undeveloped immune systems, and rapid vascularization.

Quantifiable outcome

  • Treatment prediction accuracy of 80% compared to clinical outcomes
  • +6 more outcomes

Companies that use BioReperia

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

BioReperia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

BioReperia partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Charles River LaboratoriescoreChannel Partner/ Reseller/ Distributor · 18 December 2019Strategic partnership where Charles River Laboratories provides access to their Tumor Compendium of over 1000 fully characterized PDX models. The ZTX platform supports all PDX models from Charles River, and collaborative studies have been presented at AACR conferences. The partnership enables pharmaceutical companies to screen PDX models using the zebrafish platform before mouse studies.
  • InVivo BioSystemsminorStrategic or Co-development PartnerCo-hosted webinar on 'Advancing Human Disease Research with Zebrafish Models: From Tank to Bedside' with Joseph Bruckner, PhD from InVivo Biosystems. Partnership for knowledge sharing and cross-promotion in zebrafish model research.
  • Inaphea BiolabsminorStrategic or Co-development PartnerPartner service provider offering advanced drug discovery services including biomarker analysis, disease modeling, and preclinical screening. Collaboration for joint service delivery and market expansion.
  • Cantargia ABminorStrategic or Co-development PartnerCollaboration for pre-clinical evaluation of CAN04 antibody for lung and pancreatic cancer. AACR 2020 poster presentation showed synergistic effects of CAN04 with cisplatin, including anti-metastatic activity in cisplatin-resistant models.
  • Mount SinaiminorStrategic or Co-development PartnerAcademic partner for co-hosted webinar on 'Advancing Prostate Cancer Targeted Therapy: Breakthroughs Using Zebrafish Tumor Xenograft Models' with Sujit Nair, PhD from Icahn School of Medicine at Mount Sinai.
  • NEOGAP TherapeuticsminorStrategic or Co-development PartnerAcademic collaboration for evaluation of checkpoint inhibitors and autologous T cell activation on primary tumor tissue using zebrafish tumor xenograft models.
  • Karolinska InstituteminorStrategic or Co-development PartnerAcademic collaboration contributing to AML study published in Leukemia journal, strengthening validation of DCPS as therapeutic target for acute myeloid leukemia.
  • Region ÖstergötlandminorStrategic or Co-development PartnerRegional healthcare provider collaboration for ovarian cancer patient treatment planning using zebrafish tumor-derived xenograft models.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

BioReperia competitors and assessment

Company assessment

Broad incumbents

  • WuXi AppTec: Global CRO/CDMO with comprehensive preclinical oncology and drug discovery services. Competes for the same biopharma preclinical budgets though with a much broader service portfolio.
  • Charles River Laboratories: Global CRO with extensive preclinical oncology and PDX model offerings, and BioReperia's principal strategic channel partner for Tumor Compendium access. Comparable as an oncology preclinical services incumbent, though much broader in scope.
  • Crown Bioscience (JSR Life Sciences): Global preclinical and translational CRO with a large PDX and oncology model portfolio. Comparable as a competitor for preclinical oncology drug discovery budgets at biopharma customers.
  • Inotiv: Preclinical CRO with model development, toxicology, and translational research services, including oncology models. Comparable as a broad preclinical services competitor.

Emerging players

  • InVivo BioSystems: Specialized zebrafish CRO offering in-vivo disease modeling and toxicology services. Direct competitor in zebrafish-based preclinical research and listed BioReperia partner.
  • Inaphea Biolabs: Partner and emerging CRO offering biomarker analysis, disease modeling, and preclinical screening services, including zebrafish expertise. Comparable as a smaller emerging preclinical CRO with adjacent capabilities.
  • Hera BioLabs: Specialized preclinical CRO with focus on patient-derived and humanized models for oncology and immuno-oncology drug development. Comparable emerging player in preclinical oncology CRO services.

Direct peers

  • Champions Oncology: Specialized oncology CRO focused on patient-derived xenograft models, tumor profiling, and preclinical drug development. Closely comparable service offering for biopharma preclinical programs.
  • ZeClinics: Zebrafish-focused CRO providing preclinical drug discovery, safety pharmacology, and toxicity services. Direct competitor in zebrafish-based CRO services for pharma and biotech.
  • Phylonix Services: Early commercial zebrafish CRO offering in-vivo drug efficacy and toxicity assessments. Direct competitor in the same zebrafish preclinical services niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

BioReperia compliance and trust

Trust signal

Compliance4 records

BioReperia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioReperia leadership team

Management profile

Number of profiles

Profiles7 records

BioReperia subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

BioReperia funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioReperia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioReperia

What does BioReperia do?

BioReperia provides contract research services using its proprietary Zebrafish Tumor Xenograft (ZTX) platform for preclinical oncology drug discovery and a CE-certified precision medicine diagnostic service. The biopharma offering (ZTX ONCOLEADS) evaluates tumor efficacy, metastasis, immune oncology, screening, toxicology, and disease models, delivering lead candidate selection in 5 days. The clinical offering (ZTX PREDICT) tests patient tumor biopsies to identify the most effective cancer treatment for individual patients within 5 days, serving pharmaceutical companies, biotech firms, academic institutions, and clinical healthcare providers.

Is BioReperia a public or private company?

BioReperia is a private company. It is classified as venture growth investor backed and is currently operating.

When was BioReperia founded?

BioReperia was founded in 2015. It employs 11 to 50 people.

Where is BioReperia based?

BioReperia is headquartered in Linköping, Sweden, in the Europe region.

How does BioReperia make money?

Three revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are clinical Diagnostic Services (ZTX PREDICT) and patient Stratification for Clinical Trials.

Who are BioReperia's main competitors?

Broad incumbents on record are WuXi AppTec, Charles River Laboratories, Crown Bioscience (JSR Life Sciences) and Inotiv. Emerging players are InVivo BioSystems, Inaphea Biolabs and Hera BioLabs. Direct peers are Champions Oncology, ZeClinics and Phylonix Services.

Does BioReperia have an API?

No public API is recorded for BioReperia.

What industry is BioReperia in?

BioReperia's product category is Preclinical Oncology Drug Discovery Services. Its primary akta.pro industry code is HLAGAEAI, Sample Logistics, Biorepository & IVD Kit Management (Trial Support), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales